Clinical trials
Recurrent clinical trials
Below are recruiting recurrent clinical trials, each written for real people, not researchers. We’re tracking 1,384 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05557578RecruitingPhase 2
New drug before surgery for resectable bile duct cancer
This Phase 2 trial tests a “neoadjuvant” (before-surgery) treatment for resectable intrahepatic cholangiocarcinoma (bile duct cancer in the liver) that has higher risk of coming back. It aims to shrink or control the cancer before the operation, and to see if patients can safely undergo surgery afterward.
Hangzhou, ZhejiangAges 18–75 - NCT05920863RecruitingPhase 2
Lenvatinib, immunotherapy, plus liver artery treatment before surgery
This Phase 2 trial tests whether giving lenvatinib and immunotherapy along with TACE (a liver artery treatment) before surgery can lower the risk of hepatocellular carcinoma coming back after surgery. It targets people with certain higher-risk early-stage liver tumors (CNLC IB/IIA).
Hangzhou, ZhejiangAges 18–75 - NCT07410494RecruitingPhase 1/Phase 2
Personalized donor cell therapy for advanced solid tumors
This trial tests a personalized cell therapy (CAR-NK) using donor immune cells that are engineered to find and attack one or two markers on advanced solid tumors. It may be an option for people whose tumors have these specific markers and have exhausted other treatments.
Beijing, Beijing MunicipalityAges 8–85 - NCT05974358Recruiting
Compare two bowel-connection methods to prevent Crohn’s flare-ups
This trial tests whether a specific type of bowel connection during Crohn’s surgery can lower the chances that the disease comes back. It may help people having their first ileocolonic (small-to-large bowel) surgery for certain Crohn’s complications.
BesançonAges 18–75 - NCT07398170Recruiting
Searching for tumor cells in fluid for recurrent meningioma
This study looks for tumor cells in your blood or spinal fluid to see if they can help track aggressive meningiomas that have come back. It may help doctors understand your cancer better and guide future treatments.
Montpellier, FranceAges 18 years+ - NCT07405086RecruitingPhase 4
Morning versus afternoon immunotherapy for advanced cancer
This trial tests whether getting your immunotherapy infusion in the morning or in the afternoon makes any difference in how well it works. If you have certain types of advanced cancer and are about to start a standard FDA-approved immunotherapy, this study may help you and others by finding the best time of day for treatment.
Portland, OregonAges 18 years+ - NCT07393555RecruitingPhase 2
Treatment for advanced lung cancer after targeted therapy and chemotherapy
This study tests a new treatment for advanced non-small cell lung cancer that has stopped responding to targeted therapy and chemotherapy. The goal is to find a treatment that works better for people whose cancer has certain genetic changes.
Berkeley, CaliforniaAges 18 years+ - NCT07392957RecruitingPhase 1/Phase 2
Testing CTX-009 with CTX-471 for recurrent glioblastoma
This trial tests a combination of two experimental drugs, CTX-009 and CTX-471, for people whose glioblastoma has returned. The goal is to see if these drugs can help control the tumor.
St Louis, MissouriAges 18 years+ - NCT07395505Enrolling by invitation
Surgery for advanced rectal or anal cancer
This trial studies the results of a major surgery called pelvic exenteration for patients with advanced rectal or anal cancer that has spread to nearby tissues or bones but not to distant organs. The goal is to see how well the surgery works and how patients recover afterward.
TaoyuanAges 20 years+ - NCT05417932RecruitingPhase 1/Phase 2
Cell therapy for hepatitis B–related liver cancer
This Phase 1/2 study tests a lab-made cell treatment (SCG101) for people with hepatitis B–related liver cancer who have already had standard treatments. It aims to shrink tumors and improve outcomes in carefully selected patients.
New York, New YorkAges 18–70 - NCT04095572RecruitingPhase 4
Prevention options for recurring bladder infections in women
This trial studies different ways to prevent repeated bladder (urinary tract) infections in women. It may help people who keep getting these infections by testing safer or more effective prevention strategies.
BaselAges 18–70 - NCT06725433Recruiting
Nissen vs Dor repair for hiatal hernia
This trial compares two types of hiatal hernia repair: Nissen and Dor fundoplication. It aims to see which one works better for patients having keyhole surgery for a large hiatal hernia.
KuopioAges 18 years+ - NCT07377747Recruiting
Study of treatment for recurrent retroperitoneal liposarcoma
This study looks at how well standard treatments work for people whose liposarcoma has come back in the same area. It helps doctors understand best ways to manage this rare cancer.
Atlanta, GeorgiaAges 18 years+ - NCT07371403Recruiting
Car-t cell therapy for relapsed or refractory acute lymphoblastic leukemia
This trial tests a type of immunotherapy called CAR-T cells that are made from your own blood cells and are designed to find and destroy leukemia cells. It is for patients whose leukemia has come back or hasn't gone away after other treatments.
AmmanAges 1 year+ - NCT07362134Enrolling by invitation
Pulsed-field ablation for recurrent atypical atrial flutter
This study tests a new type of energy called pulsed-field ablation (PFA) to treat a specific kind of irregular heartbeat called atypical atrial flutter that keeps coming back after a prior ablation. It aims to see if this approach can safely stop the abnormal rhythm.
TaipeiAges 18–80 - NCT07363252Recruiting
Study of why lung cancer returns after osimertinib treatment
This study looks at why lung cancer returns in people who took the targeted pill osimertinib after surgery. If your cancer has come back, researchers will test your tumor or blood sample to understand how the cancer changed.
Bari, BAAges 18 years+ - NCT05464875Recruiting
Testing avapritinib for advanced GI stromal tumors
This study looks at how well avapritinib works and how safe it is for people with metastatic or unresectable gastrointestinal stromal tumors (GIST). It focuses on whether the tumor has certain marker and gene features and whether you can tolerate related medications.
GuangzhouAges 18 years+ - NCT07357597RecruitingPhase 4
Preventing mouth sores during breast or lung cancer treatment
This trial tests whether a steroid mouthwash can prevent mouth sores caused by the drug Datopotamab Deruxtecan (Dato-DXd). It is for people with certain types of advanced breast cancer or lung cancer who are about to start Dato-DXd for the first time.
Tucson, ArizonaAges 18 years+ - NCT07357311Recruiting
Screening for Fear of Cancer Recurrence
This study aims to help people with breast or lung cancer who worry about their cancer coming back. You will answer questionnaires about your fears, so the care team can better support you.
ParisAges 18 years+ - NCT06208462RecruitingPhase 2
Combination therapy before surgery for high-risk bile duct cancer
This trial tests a combination of chemotherapy directly into the liver artery, an immunotherapy drug, and a targeted therapy pill before surgery for a type of bile duct cancer that has a high chance of coming back. The goal is to see if this approach can improve outcomes for patients whose cancer is still removable but has certain high-risk features.
Nanjing, JiangsuAges 18–75 - NCT07346144RecruitingPhase 1/Phase 2
Gene therapy study for high-grade glioma
This trial tests a new gene therapy given directly into the brain tumor. It's for people with high-grade glioma, either newly diagnosed or after one recurrence, to see if it can help control the tumor.
Columbus, OhioAges 18–70 - NCT07347171RecruitingPhase 1
Testing CG009301 for blood cancers that returned or didn't respond
This trial tests a new drug called CG009301 for people with blood cancers that have come back or haven't responded to standard treatments. The goal is to see if the drug is safe and works against these cancers.
NanchangAges 18–75 - NCT07348042RecruitingPhase 1
Study of RGL-270 with or without Adebelimab for high-risk solid tumors
This trial tests a new treatment (RGL-270) alone or with another drug (Adebelimab) to prevent cancer from coming back after surgery. It is for people with solid tumors that have a high chance of returning.
ShanghaiAges 18–75 - NCT07346157RecruitingPhase 1/Phase 2
Testing a thyroid hormone drug with chemo for relapsed medulloblastoma
This trial tests whether adding a thyroid hormone (liothyronine) to a standard chemotherapy combination (bevacizumab, irinotecan, temozolomide) can help children and young adults with medulloblastoma that has come back after initial treatment.
San Francisco, CaliforniaAges 1–25
Hear when a new Recurrent trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for recurrent?
- Yes. Clin2 currently lists 1,384 recruiting recurrent studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a recurrent trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a recurrent trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.